546 related articles for article (PubMed ID: 27551741)
1. Reduction Sensitive PEG Hydrogels for Codelivery of Antigen and Adjuvant To Induce Potent CTLs.
Kapadia CH; Tian S; Perry JL; Luft JC; DeSimone JM
Mol Pharm; 2016 Oct; 13(10):3381-3394. PubMed ID: 27551741
[TBL] [Abstract][Full Text] [Related]
2. Extending antigen release from particulate vaccines results in enhanced antitumor immune response.
Kapadia CH; Tian S; Perry JL; Sailer D; Christopher Luft J; DeSimone JM
J Control Release; 2018 Jan; 269():393-404. PubMed ID: 29146244
[TBL] [Abstract][Full Text] [Related]
3. Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs.
Mochizuki S; Morishita H; Kobiyama K; Aoshi T; Ishii KJ; Sakurai K
J Control Release; 2015 Dec; 220(Pt A):495-502. PubMed ID: 26562685
[TBL] [Abstract][Full Text] [Related]
4. Immunostimulatory CpG-DNA and PSA-peptide vaccination elicits profound cytotoxic T cell responses.
Maurer T; Pournaras C; Aguilar-Pimentel JA; Thalgott M; Horn T; Heck M; Heit A; Kuebler H; Gschwend JE; Nawroth R
Urol Oncol; 2013 Oct; 31(7):1395-401. PubMed ID: 21982682
[TBL] [Abstract][Full Text] [Related]
5. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
6. Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity.
Varypataki EM; van der Maaden K; Bouwstra J; Ossendorp F; Jiskoot W
AAPS J; 2015 Jan; 17(1):216-26. PubMed ID: 25387996
[TBL] [Abstract][Full Text] [Related]
7. Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis.
Xu Z; Ramishetti S; Tseng YC; Guo S; Wang Y; Huang L
J Control Release; 2013 Nov; 172(1):259-265. PubMed ID: 24004885
[TBL] [Abstract][Full Text] [Related]
8. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide.
Miconnet I; Koenig S; Speiser D; Krieg A; Guillaume P; Cerottini JC; Romero P
J Immunol; 2002 Feb; 168(3):1212-8. PubMed ID: 11801657
[TBL] [Abstract][Full Text] [Related]
9. The adjuvant effect of melanin is superior to incomplete Freund's adjuvant in subunit/peptide vaccines in mice.
Cuzzubbo S; Banissi C; Rouchon MS; Tran T; Tanchot C; Tartour E; Carpentier AF
Cancer Immunol Immunother; 2020 Dec; 69(12):2501-2512. PubMed ID: 32561966
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant.
Jérôme V; Graser A; Müller R; Kontermann RE; Konur A
J Immunother; 2006; 29(3):294-305. PubMed ID: 16699372
[TBL] [Abstract][Full Text] [Related]
11. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.
Schmidt ST; Olsen CL; Franzyk H; Wørzner K; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
Eur J Pharm Biopharm; 2019 Jul; 140():29-39. PubMed ID: 31055066
[TBL] [Abstract][Full Text] [Related]
13. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
14. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E; Celis E
J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
[TBL] [Abstract][Full Text] [Related]
15. Ferritin protein cage nanoparticles as versatile antigen delivery nanoplatforms for dendritic cell (DC)-based vaccine development.
Han JA; Kang YJ; Shin C; Ra JS; Shin HH; Hong SY; Do Y; Kang S
Nanomedicine; 2014 Apr; 10(3):561-9. PubMed ID: 24262997
[TBL] [Abstract][Full Text] [Related]
16. PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses.
Ma W; Chen M; Kaushal S; McElroy M; Zhang Y; Ozkan C; Bouvet M; Kruse C; Grotjahn D; Ichim T; Minev B
Int J Nanomedicine; 2012; 7():1475-87. PubMed ID: 22619507
[TBL] [Abstract][Full Text] [Related]
17. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.
Cornet S; Menez-Jamet J; Lemonnier F; Kosmatopoulos K; Miconnet I
Vaccine; 2006 Mar; 24(11):1880-8. PubMed ID: 16300869
[TBL] [Abstract][Full Text] [Related]
18. Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides.
Takahashi H; Misato K; Aoshi T; Yamamoto Y; Kubota Y; Wu X; Kuroda E; Ishii KJ; Yamamoto H; Yoshioka Y
Front Immunol; 2018; 9():783. PubMed ID: 29720976
[TBL] [Abstract][Full Text] [Related]
19. Tunable T cell immunity towards a protein antigen using polymersomes vs. solid-core nanoparticles.
Stano A; Scott EA; Dane KY; Swartz MA; Hubbell JA
Biomaterials; 2013 Jun; 34(17):4339-46. PubMed ID: 23478034
[TBL] [Abstract][Full Text] [Related]
20. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
